Strategy & Mission

Marinomed's vision is to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology. 

Therefore, it is our mission to provide patients and physicians with powerful technologies that significantly improve patients' quality of life. Our two proprietary and validated platforms, Carragelose and Marinosolv, provide the basis for novel medicines to treat indications with unmet medical needs.

With our passion for scientific progress and our expertise in respiratory, infectious, immune and eye diseases, we strive to create sustainable value for patients, health care systems, the Company and our stakeholders.

We pursue a strategy based on a mix of commercializing our late-stage assets, development of our own pipeline products and offering formulation development for our Solv4U costumers. Our strategic priorities are as follows:

1. Growth in the Carragelose OTC business through new partnerships and supporting current partners in market access with existing and new products in existing and new markets;
2. Expansion of business development activities with a focus on assets that are sufficiently advanced to start a partnering process. This includes new products in the Carragelose portfolio (allergy and eye drop product) as well as our pipeline projects in late development phases (Budesolv (MAM-1004-1) and Tacrosolv (MAM-1003-1));
3. Long-term adherence to our mission by inventing, developing and selecting promising pipeline programs for indications with high unmet medical needs, funded through the Company’s cash flows.

Marinomed develops pharmaceutical products and medical devices in the therapeutic areas of virology and immunology. Marinomed's core competencies are preclinical and early research and development with the aim of generating intellectual property. In the area of medical devices based on Carragelose, Marinomed acts as a wholesaler. In the area of pharmaceutical products, which are essentially based on Marinosolv technology, the Company grants licenses to pharmaceutical companies during the clinical development phase.

Marinomed develops non-prescription (OTC) medical devices up to approval. Subsequently, they are produced by contract manufacturers and outlicensed to partners who market and distribute the products worldwide. The Company’s sales partners for OTC products are mostly well-known pharmaceutical companies with licenses for specific geographical regions. With a lean supply chain organization, the Company currently supervises and manages 20 (31.12.2023: 18, 2022: 17) commercialization partners for more than 40 countries in the OTC segment. Most pharmaceutical companies also use their licenses to list Carragelose on the product description, which ensures that Marinomed is visible on most products via the Carragelose brand name. Marinomed generates revenue from OTC products via license payments and the sale of goods.

For the development of Rx (prescription) pharmaceutical products, Marinomed strives to find partners during or after phase II clinical studies. In these highly regulated and particularly specific markets, it is of utmost importance to have a financially solid expert partner on board, who can add indication-specific expertise and financial power to regulatory processes and clinical development.

Classic pharma deals are the goal in the Rx segment and gaining Luoxin Pharmaceutical as a partner was a first step. These deals comprise upfront, milestone and royalty payments but rely on the partner for the entire commercialization value chain from manufacturing to distribution. This enables Marinomed to concentrate on its core expertise – of research and development – the elements in the value chain contributing the highest value.